Standard BioTools Inc. Selling, General and Administrative Expense
Standard BioTools Inc. (LAB) reported Selling, General and Administrative Expense of $16.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Standard BioTools Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $16.39M, a 41.69% decline year-over-year.
- Standard BioTools Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $18.61M, a 37.61% decline year-over-year.
- Standard BioTools Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $25.34M, a 7.25% decline year-over-year.
- Standard BioTools Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $26.59M, a 8.70% increase year-over-year.
- Standard BioTools Inc. selling, general and administrative expense for fiscal 2025 was $109.86M, a 6.60% increase from fiscal 2024.
- Standard BioTools Inc. selling, general and administrative expense for fiscal 2024 was $103.06M, a 17.73% increase from fiscal 2023.
- Standard BioTools Inc. selling, general and administrative expense for fiscal 2023 was $87.54M, a 14.41% decline from fiscal 2022.
- Standard BioTools Inc. selling, general and administrative expense for fiscal 2022 was $102.28M, a 3.44% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.39M 10-Q · filed 2026-08-05 | $34.99M 10-Q · filed 2026-08-05 | $60.33M derived: sum of 3 quarters · filed 2026-08-05 | $86.93M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $18.61M 10-Q · filed 2026-05-06 | $43.94M derived: sum of 2 quarters · filed 2026-05-06 | $70.54M derived: sum of 3 quarters · filed 2026-05-06 | $98.64M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $25.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $51.93M derived: sum of 2 quarters · filed 2026-03-16 | $80.04M derived: sum of 3 quarters · filed 2026-08-05 | $109.86M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $26.59M 10-Q · filed 2025-11-04 | $54.70M derived: sum of 2 quarters · filed 2026-08-05 | $84.52M 10-Q · filed 2025-11-04 | $111.84M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $28.11M 10-Q · filed 2026-08-05 | $57.93M 10-Q · filed 2026-08-05 | $85.25M derived: sum of 3 quarters · filed 2026-08-05 | $109.71M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $29.82M 10-Q · filed 2026-05-06 | $38.71M 10-Q · filed 2025-05-06 | $57.14M derived: sum of 2 quarters · filed 2026-05-06 | $81.61M derived: sum of 3 quarters · filed 2026-05-06 | $106.47M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $27.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $51.78M derived: sum of 2 quarters · filed 2026-03-16 | $76.64M derived: sum of 3 quarters · filed 2026-03-16 | $103.06M 10-K · filed 2026-03-16 | $156.61M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $24.47M 10-Q · filed 2025-11-04 | $34.40M 10-Q · filed 2024-11-06 | $49.33M derived: sum of 2 quarters · filed 2025-11-04 | $75.74M 10-Q · filed 2025-11-04 | $119.02M 10-Q · filed 2024-11-06 | $117.62M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-06-30 | $24.86M 10-Q · filed 2025-08-15 | $37.67M 10-Q · filed 2024-08-06 | $51.27M 10-Q · filed 2025-08-15 | $84.62M 10-Q · filed 2024-08-06 | $93.16M derived: sum of 3 quarters · filed 2026-03-16 | $115.45M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-03-31 | $46.94M 10-Q · filed 2025-05-06 | $68.30M derived: sum of 2 quarters · filed 2026-03-16 | $90.59M derived: sum of 3 quarters · filed 2026-03-16 | $113.19M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2023-12-31 | $21.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $43.65M derived: sum of 2 quarters · filed 2026-03-16 | $66.25M derived: sum of 3 quarters · filed 2026-03-16 | $87.54M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | $22.29M 10-Q · filed 2024-11-06 | $44.89M derived: sum of 2 quarters · filed 2024-11-06 | $66.19M 10-Q · filed 2024-11-06 | $86.41M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | $22.60M 10-Q · filed 2024-08-06 | $43.90M 10-Q · filed 2024-08-06 | $64.12M derived: sum of 3 quarters · filed 2025-03-11 | $90.46M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-03-31 | $21.30M 10-Q · filed 2024-05-09 | $22.31M 10-Q · filed 2023-05-09 | $41.52M derived: sum of 2 quarters · filed 2025-03-11 | $67.86M derived: sum of 3 quarters · filed 2025-03-11 | $97.94M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2022-12-31 | $20.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $46.56M derived: sum of 2 quarters · filed 2025-03-11 | $76.65M derived: sum of 3 quarters · filed 2025-03-11 | $102.28M 10-K · filed 2025-03-11 | $114.76M 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $26.34M 10-Q · filed 2023-11-07 | $29.60M 10-Q · filed 2022-11-09 | $56.42M derived: sum of 2 quarters · filed 2023-11-07 | $82.06M 10-Q · filed 2023-11-07 | $90.86M 10-Q · filed 2022-11-09 | $110.26M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $30.08M 10-Q · filed 2023-08-08 | $30.38M 10-Q · filed 2022-08-09 | $59.57M 10-Q · filed 2023-08-08 | $61.26M 10-Q · filed 2022-08-09 | $83.92M derived: sum of 3 quarters · filed 2023-08-08 | $107.99M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $30.88M 10-Q · filed 2023-05-09 | $53.84M derived: sum of 2 quarters · filed 2023-05-09 | $77.91M derived: sum of 3 quarters · filed 2023-05-09 | $102.16M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $22.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $47.03M derived: sum of 2 quarters · filed 2023-03-14 | $71.28M derived: sum of 3 quarters · filed 2023-03-14 | $98.89M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $24.07M 10-Q · filed 2022-11-09 | $48.32M derived: sum of 2 quarters · filed 2022-11-09 | $75.93M 10-Q · filed 2022-11-09 | $107.86M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $24.25M 10-Q · filed 2022-08-09 | $51.86M 10-Q · filed 2022-08-09 | $83.79M derived: sum of 3 quarters · filed 2022-08-09 | $106.45M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $27.61M 10-Q · filed 2022-05-09 | $59.54M derived: sum of 2 quarters · filed 2022-05-09 | $82.20M derived: sum of 3 quarters · filed 2022-05-09 | $102.81M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $31.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $54.59M derived: sum of 2 quarters · filed 2022-03-08 | $75.21M derived: sum of 3 quarters · filed 2022-03-08 | $97.90M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $22.66M 10-Q · filed 2021-11-09 | $43.27M derived: sum of 2 quarters · filed 2021-11-09 | $65.97M 10-Q · filed 2021-11-09 | $84.76M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2020-06-30 | $20.62M 10-Q · filed 2021-08-06 | $43.31M 10-Q · filed 2021-08-06 | $62.10M derived: sum of 3 quarters · filed 2022-03-08 | $82.83M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2020-03-31 | $22.70M 10-Q · filed 2021-05-07 | $41.49M derived: sum of 2 quarters · filed 2022-03-08 | $62.22M derived: sum of 3 quarters · filed 2022-03-08 | $84.35M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2019-12-31 | $18.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $39.52M derived: sum of 2 quarters · filed 2022-03-08 | $61.65M derived: sum of 3 quarters · filed 2022-03-08 | $84.48M 10-K · filed 2022-03-08 | ||||
| 2019-09-30 | $20.73M 10-Q · filed 2020-11-09 | $42.86M derived: sum of 2 quarters · filed 2020-11-09 | $65.69M 10-Q · filed 2020-11-09 | $87.66M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $22.13M 10-Q · filed 2020-08-07 | $44.96M 10-Q · filed 2020-08-07 | $66.93M derived: sum of 3 quarters · filed 2021-02-25 | $86.95M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $22.82M 10-Q · filed 2020-05-11 | $44.80M derived: sum of 2 quarters · filed 2021-02-25 | $64.81M derived: sum of 3 quarters · filed 2021-02-25 | $83.80M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $21.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $41.99M derived: sum of 2 quarters · filed 2021-02-25 | $60.98M derived: sum of 3 quarters · filed 2021-02-25 | $79.78M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $20.02M 10-Q · filed 2019-11-08 | $39.01M derived: sum of 2 quarters · filed 2019-11-08 | $57.81M 10-Q · filed 2019-11-08 | $73.67M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $18.99M 10-Q · filed 2019-08-07 | $37.79M 10-Q · filed 2019-08-07 | $53.66M derived: sum of 3 quarters · filed 2020-02-27 | $73.76M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $18.80M 10-Q · filed 2019-05-07 | $34.67M derived: sum of 2 quarters · filed 2020-02-27 | $54.77M derived: sum of 3 quarters · filed 2020-02-27 | $75.75M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $35.97M derived: sum of 2 quarters · filed 2020-02-27 | $56.94M derived: sum of 3 quarters · filed 2020-02-27 | $79.52M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $20.10M 10-Q · filed 2018-11-06 | $41.08M derived: sum of 2 quarters · filed 2018-11-06 | $63.65M 10-Q · filed 2018-11-06 | $86.42M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-06-30 | $20.98M 10-Q · filed 2018-08-08 | $43.55M 10-Q · filed 2018-08-08 | $66.32M derived: sum of 3 quarters · filed 2019-03-18 | $87.44M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | $22.58M 10-Q · filed 2018-05-08 | $45.34M derived: sum of 2 quarters · filed 2019-03-18 | $66.47M derived: sum of 3 quarters · filed 2019-03-18 | $90.31M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | $22.77M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $43.89M derived: sum of 2 quarters · filed 2019-03-18 | $67.74M derived: sum of 3 quarters · filed 2019-03-18 | $93.21M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | $21.12M 10-Q · filed 2017-11-07 | $44.97M derived: sum of 2 quarters · filed 2017-11-07 | $70.44M 10-Q · filed 2017-11-07 | $92.53M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-06-30 | $23.84M 10-Q · filed 2017-08-08 | $49.32M 10-Q · filed 2017-08-08 | $71.41M derived: sum of 3 quarters · filed 2018-03-08 | $90.96M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-03-31 | $25.48M 10-Q · filed 2017-05-09 | $47.56M derived: sum of 2 quarters · filed 2018-03-08 | $67.12M derived: sum of 3 quarters · filed 2018-03-08 | $88.34M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2015-12-31 | $22.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $41.64M derived: sum of 2 quarters · filed 2018-03-08 | $62.87M derived: sum of 3 quarters · filed 2018-03-08 | $82.96M 10-K · filed 2018-03-08 | ||||
| 2015-09-30 | $19.56M 10-Q · filed 2016-11-09 | $40.78M derived: sum of 2 quarters · filed 2016-11-09 | $60.87M 10-Q · filed 2016-11-09 | $79.71M derived: sum of 4 quarters · filed 2017-03-03 | ||||
| 2015-06-30 | $21.22M 10-Q · filed 2016-08-09 | $41.32M 10-Q · filed 2016-08-09 | $60.15M derived: sum of 3 quarters · filed 2017-03-03 | $78.73M derived: sum of 4 quarters · filed 2017-03-03 | ||||
| 2015-03-31 | $20.09M 10-Q · filed 2016-05-09 | $38.93M derived: sum of 2 quarters · filed 2017-03-03 | $57.51M derived: sum of 3 quarters · filed 2017-03-03 | $76.16M derived: sum of 4 quarters · filed 2017-03-03 | ||||
| 2014-12-31 | $18.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $37.41M derived: sum of 2 quarters · filed 2017-03-03 | $56.07M derived: sum of 3 quarters · filed 2017-03-03 | $71.32M 10-K · filed 2017-03-03 | ||||
| 2014-09-30 | $18.57M 10-Q · filed 2015-11-09 | $37.23M derived: sum of 2 quarters · filed 2015-11-09 | $52.49M 10-Q · filed 2015-11-09 | $66.06M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $18.66M 10-Q · filed 2015-08-10 | $33.91M 10-Q · filed 2015-08-10 | $47.48M derived: sum of 3 quarters · filed 2016-02-29 | $59.58M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $15.26M 10-Q · filed 2015-05-11 | $28.83M derived: sum of 2 quarters · filed 2016-02-29 | $40.93M derived: sum of 3 quarters · filed 2016-02-29 | $52.52M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $25.67M derived: sum of 2 quarters · filed 2016-02-29 | $37.27M derived: sum of 3 quarters · filed 2016-02-29 | $48.41M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $12.10M 10-Q · filed 2014-11-06 | $23.69M derived: sum of 2 quarters · filed 2014-11-06 | $34.84M 10-Q · filed 2014-11-06 | $45.39M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2013-06-30 | $11.60M 10-Q · filed 2014-08-04 | $22.74M 10-Q · filed 2014-08-04 | $33.30M derived: sum of 3 quarters · filed 2015-02-26 | $42.40M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2013-03-31 | $11.15M 10-Q · filed 2014-05-12 | $21.70M derived: sum of 2 quarters · filed 2015-02-26 | $30.80M derived: sum of 3 quarters · filed 2015-02-26 | $40.22M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2012-12-31 | $10.55M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $19.65M derived: sum of 2 quarters · filed 2015-02-26 | $29.07M derived: sum of 3 quarters · filed 2015-02-26 | $38.48M 10-K · filed 2015-02-26 | ||||
| 2012-09-30 | $9.10M 10-Q · filed 2013-11-07 | $18.52M derived: sum of 2 quarters · filed 2013-11-07 | $27.93M 10-Q · filed 2013-11-07 | $35.89M derived: sum of 4 quarters · filed 2014-03-12 | ||||
| 2012-06-30 | $9.42M 10-Q · filed 2013-08-07 | $18.82M 10-Q · filed 2013-08-07 | $26.79M derived: sum of 3 quarters · filed 2014-03-12 | $34.84M derived: sum of 4 quarters · filed 2014-03-12 | ||||
| 2012-03-31 | $9.40M 10-Q · filed 2013-05-09 | $17.37M derived: sum of 2 quarters · filed 2014-03-12 | $25.42M derived: sum of 3 quarters · filed 2014-03-12 | $33.27M derived: sum of 4 quarters · filed 2014-03-12 | ||||
| 2011-12-31 | $7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $16.02M derived: sum of 2 quarters · filed 2014-03-12 | $23.86M derived: sum of 3 quarters · filed 2014-03-12 | $31.30M 10-K · filed 2014-03-12 | ||||
| 2011-09-30 | $8.05M 10-Q · filed 2012-11-09 | $15.90M derived: sum of 2 quarters · filed 2012-11-09 | $23.34M 10-Q · filed 2012-11-09 | $29.21M derived: sum of 4 quarters · filed 2013-03-12 | ||||
| 2011-06-30 | $7.84M 10-Q · filed 2012-08-14 | $15.29M 10-Q · filed 2012-08-14 | $21.16M derived: sum of 3 quarters · filed 2013-03-12 | $26.81M derived: sum of 4 quarters · filed 2013-03-12 | ||||
| 2011-03-31 | $7.44M 10-Q · filed 2012-05-15 | $13.31M derived: sum of 2 quarters · filed 2013-03-12 | $18.96M derived: sum of 3 quarters · filed 2013-03-12 | $24.87M derived: sum of 4 quarters · filed 2013-03-12 | ||||
| 2010-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $11.52M derived: sum of 2 quarters · filed 2013-03-12 | $17.42M derived: sum of 3 quarters · filed 2013-03-12 | $23.55M 10-K · filed 2013-03-12 | ||||
| 2010-09-30 | $5.65M 10-Q · filed 2011-11-14 | $11.55M derived: sum of 2 quarters · filed 2011-11-14 | $17.67M 10-Q · filed 2011-11-14 | |||||
| 2010-06-30 | $5.90M 10-Q · filed 2011-08-09 | $12.02M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $19.65M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |